Supplementary Data S6 from Optimizing Precision Medicine for Breast Cancer Brain Metastases with Functional Drug Response Assessment

Morikawa, Aki; Li, Jinju; Ulintz, Peter; Cheng, Xu; Apfel, Athena; Robinson, Dan; Hopkins, Alex; Kumar-Sinha, Chandan; Wu, Yi-Mi; Serhan, Habib; Verbal, Kait; Thomas, Dafydd; Hayes, Daniel F.; Chinnaiyan, Arul M.; Baladandayuthapani, Veerabhadran; Heth, Jason; Soellner, Matthew B.; Merajver, Sofia D.; Merrill, Nathan

doi:10.1158/2767-9764.23553324.v1

crc-22-0492-s06.pdf (63.86 kB)

Supplementary Data S6 from Optimizing Precision Medicine for Breast Cancer Brain Metastases with Functional Drug Response Assessment

journal contribution

posted on 2023-06-21, 14:20 authored by Aki Morikawa, Jinju Li, Peter Ulintz, Xu Cheng, Athena Apfel, Dan Robinson, Alex Hopkins, Chandan Kumar-Sinha, Yi-Mi Wu, Habib Serhan, Kait Verbal, Dafydd Thomas, Daniel F. Hayes, Arul M. Chinnaiyan, Veerabhadran Baladandayuthapani, Jason Heth, Matthew B. Soellner, Sofia D. Merajver, Nathan Merrill

Clinicopathologic characteristics of source patients for brain metastases PDX models: Group B.

Funding

American Society of Clinical Oncology (ASCO)

Breast Cancer Research Foundation (BCRF)

UM | Comprehensive Cancer Center, University of Michigan (U-M Comprehensive Cancer Center)

HHS | National Institutes of Health (NIH)

History

ARTICLE ABSTRACT

Examining genomic alterations and differentially expressed pathways in brain metastases may inform future therapeutic strategies. This study supports genomically-guided therapy for BCBM and further investigation into incorporating real-time functional evaluation will increase confidence in efficacy estimations during drug development and predictive biomarker assessment for BCBM.